ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

Five-year data from clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions ...